Interchangeability of Biosimilars: A European Perspective (Q39000780)

8 September 2017

title

Interchangeability of Biosimilars: A European Perspective (English)

1 reference

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Pekka Kurki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Leon van Aerts

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Elena Wolff-Holz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Thijs Giezen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Venke Skibeli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

24 January 2017

1 reference

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

83-91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Expert perspectives on biosimilar monoclonal antibodies in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

The safety of switching between therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

The ESA scenario gets complex: from biosimilar epoetins to activin traps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Regulation and dysregulation of immunoglobulin E: a molecular and clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Danger signals: SOS to the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Adaptive immune activation: glycosylation does matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Impact of illegal trade on the quality of epoetin alfa in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Factor VIII products and inhibitor development in severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Switching treatments in haemophilia: is there a risk of inhibitor development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

A review of CT-P13: an infliximab biosimilar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Biosimilars - terms of use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0210-0

10.1007/S40259-017-0210-0

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28120313%20AND%20SRC:MED&resulttype=core&format=json